Literature DB >> 19707215

Stockpiling antiviral drugs for the next influenza pandemic.

A Patel1, S E Gorman.   

Abstract

The threat of an influenza pandemic has been at the forefront of public health preparedness for more than 5 years. The national planning effort has included stockpiling antiviral drugs in the Centers for Disease Control and Prevention's Strategic National Stockpile (SNS). This article highlights the composition of the SNS before the 2009 H1N1 pandemic and includes considerations for future antiviral stockpile purchases, focusing on emergence of oseltamivir resistance and the need for additional pediatric supplies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19707215     DOI: 10.1038/clpt.2009.142

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

1.  Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.

Authors:  Manjunath P Pai; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

Review 2.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

3.  Timely Antiviral Administration During an Influenza Pandemic: Key Components.

Authors:  Lisa M Koonin; Anita Patel
Journal:  Am J Public Health       Date:  2018-09       Impact factor: 9.308

4.  Quantification of the anti-influenza drug zanamivir in plasma using high-throughput HILIC-MS/MS.

Authors:  Niklas Lindegardh; Warunee Hanpithakpong; Benjamas Kamanikom; Jeremy Farrar; Tran Tinh Hien; Pratap Singhasivanon; Nicholas J White; Nicholas P J Day
Journal:  Bioanalysis       Date:  2011-01       Impact factor: 2.681

5.  Oseltamivir-resistant influenza A (H1N1) virus strain with an H274Y mutation in neuraminidase persists without drug pressure in infected mallards.

Authors:  Anna Gillman; Shaman Muradrasoli; Hanna Söderström; Fredrik Holmberg; Neus Latorre-Margalef; Conny Tolf; Jonas Waldenström; Gunnar Gunnarsson; Björn Olsen; Josef D Järhult
Journal:  Appl Environ Microbiol       Date:  2015-01-23       Impact factor: 4.792

6.  In Vitro Susceptibility of Canine Influenza A (H3N8) Virus to Nitazoxanide and Tizoxanide.

Authors:  Laura V Ashton; Robert L Callan; Sangeeta Rao; Gabriele A Landolt
Journal:  Vet Med Int       Date:  2010-08-12

7.  Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards.

Authors:  Josef D Järhult; Shaman Muradrasoli; John Wahlgren; Hanna Söderström; Goran Orozovic; Gunnar Gunnarsson; Caroline Bröjer; Neus Latorre-Margalef; Jerker Fick; Roman Grabic; Johan Lennerstrand; Jonas Waldenström; Ake Lundkvist; Björn Olsen
Journal:  PLoS One       Date:  2011-09-12       Impact factor: 3.240

8.  Influenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water.

Authors:  Anna Gillman; Marie Nykvist; Shaman Muradrasoli; Hanna Söderström; Michelle Wille; Annika Daggfeldt; Caroline Bröjer; Jonas Waldenström; Björn Olsen; Josef D Järhult
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

9.  Resistance mutation R292K is induced in influenza A(H6N2) virus by exposure of infected mallards to low levels of oseltamivir.

Authors:  Anna Gillman; Shaman Muradrasoli; Hanna Söderström; Johan Nordh; Caroline Bröjer; Richard H Lindberg; Neus Latorre-Margalef; Jonas Waldenström; Björn Olsen; Josef D Järhult
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

10.  Oseltamivir (Tamiflu(®)) in the environment, resistance development in influenza A viruses of dabbling ducks and the risk of transmission of an oseltamivir-resistant virus to humans - a review.

Authors:  Josef D Järhult
Journal:  Infect Ecol Epidemiol       Date:  2012-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.